Qlucore AB (QCORE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qlucore AB (QCORE) has a cash flow conversion efficiency ratio of -0.194x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.04 Million ≈ $-757.94K USD) by net assets (Skr36.30 Million ≈ $3.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QCORE net asset quality index to measure how much of total assets are equity-financed.
Qlucore AB - Cash Flow Conversion Efficiency Trend (2019–2026)
This chart illustrates how Qlucore AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Qlucore AB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Qlucore AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qlucore AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Streamline Health Solutions Inc
NASDAQ:STRM
|
-0.088x |
|
Beeks Trading Corporation Ltd
LSE:BKS
|
0.143x |
|
Mantex AB
ST:MANTEX
|
-1.685x |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
|
KATORO GOLD PLC LS-01
F:622
|
N/A |
|
Interactive Strength Inc. Common Stock
NASDAQ:TRNR
|
-0.352x |
|
Panther Metals Ltd
AU:PNT
|
-0.034x |
|
Arctic Star Exploration Corp
V:ADD
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Qlucore AB (2019–2026)
The table below shows the annual cash flow conversion efficiency of Qlucore AB from 2019 to 2026. For the full company profile with market capitalisation and key ratios, see Qlucore AB market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | Skr36.30 Million ≈ $3.91 Million |
Skr-12.46 Million ≈ $-1.34 Million |
-0.343x | -41.81% |
| 2025-04-30 | Skr58.47 Million ≈ $6.29 Million |
Skr-14.15 Million ≈ $-1.52 Million |
-0.242x | -13.00% |
| 2024-04-30 | Skr79.11 Million ≈ $8.51 Million |
Skr-16.95 Million ≈ $-1.82 Million |
-0.214x | -152.16% |
| 2023-04-30 | Skr94.73 Million ≈ $10.19 Million |
Skr-8.05 Million ≈ $-866.20K |
-0.085x | -38.02% |
| 2022-04-30 | Skr110.56 Million ≈ $11.90 Million |
Skr-6.81 Million ≈ $-732.43K |
-0.062x | -108.40% |
| 2021-04-30 | Skr36.56 Million ≈ $3.93 Million |
Skr-1.08 Million ≈ $-116.23K |
-0.030x | -126.46% |
| 2020-04-30 | Skr14.34 Million ≈ $1.54 Million |
Skr1.60 Million ≈ $172.29K |
0.112x | -40.31% |
| 2019-04-30 | Skr8.56 Million ≈ $921.47K |
Skr1.60 Million ≈ $172.29K |
0.187x | -- |
About Qlucore AB
Qlucore AB (publ) offers visualization-based bioinformatics data analysis tools for research and precision diagnostics in Sweden and internationally. It offers Qlucore Omics Explorer, a bioinformatics software for research in life science, biotech, and plant industries, as well as academia; Qlucore Insights, a software for clinical data analysis; and Qlucore Diagnostics, a software platform for m… Read more